Scientific Affairs

Saint-Maur-des-Fossés, France

Scientific Affairs

Saint-Maur-des-Fossés, France
SEARCH FILTERS
Time filter
Source Type

"Wir freuen uns über diesen Vertrauensbeweis. Die Anerkennung unserer Arbeit durch die DTRA stärkt die Positionierung von MeMed als Weltmarktführer auf dem Gebiet der immunbasierten Diagnostik von Infektionskrankheiten", bemerkte Dr. Eran Eden, CEO bei MeMed.  "Diese gemeinsame Anstrengung und unsere wachsende Zusammenarbeit mit anderen internationalen Interessenvertretern aus Industrie und Regierung wird die weltweite Verfügbarkeit unserer Tests zur Bekämpfung antimikrobieller Resistenzen ermöglichen." Während der letzten acht Jahre haben die Unternehmensmitgründer Dr. med. Kfir Oved und Dr. Eran Eden mit führenden Forschern und Klinikern aus der ganzen Welt zusammengearbeitet, um die Veränderungen zu untersuchen, die im menschlichen Immunsystem stattfinden, wenn es Infektionen bekämpft, und um eine menschliche Immunsignatur zu entwickeln, die den Unterschied zwischen bakteriellen und Virusinfektionen genau erkennt. ImmunoXpert™, das neuartige Testverfahren der ersten Generation, ist bereits in Gebrauch und hat sich an Tausenden von Patienten bewährt*. Das Testverfahren der zweiten Generation umfasste die Entwicklung einer neuen patientennahen Diagnoseplattform, die einfach zu handhaben ist und nur 15 Minuten Zeit in Anspruch nimmt. "Diese Zusammenarbeit wird uns ermöglichen, die Fertigstellung unserer patientennahen Diagnoseplattform zu beschleunigen", sagte Dr. med. Kfir Oved, CTO bei MeMed. "Die neue Plattform ermöglicht nicht nur innerhalb von Minuten Messungen unserer bakteriellen Tests im Vergleich zu viralen Tests, sondern ebnet darüber hinaus den Weg zu einer Vielzahl von Mehrfach-Proteinmessungen in Form von Schnelltests mit der Präzision einer Labordiagnostik für einen umfassenden Anwendungsbereich." "Das Projekt wird außerdem unser Testmenü zum frühen Erkennen von Infektionen bewerten und erweitern, sogar bereits in einem präsymptomatischen Krankheitsstadium, in dem noch keine Symptome vorliegen. Dies stellt zurzeit eine enorme Einschränkung unserer Fähigkeit dar, Infektionen und Epidemien unter Kontrolle zu halten", stellte Dr. Tanya Gottlieb, VP Scientific Affairs bei MeMed, fest. Die Defense Threat Reduction Agency (DTRA) wurde im Jahr 1998 als eine dem Verteidigungsministerium der Vereinigten Staaten angeschlossene Behörde gegründet und befasst sich mit der Verminderung der Bedrohung durch Massenvernichtungswaffen. Die Hauptaufgabe der DTRA besteht darin, die Bedrohung der Vereinigten Staaten und der restlichen Welt durch globale Massenvernichtungswaffen sowie improvisierte Bedrohungen einzudämmen. Dies geschieht durch Integration, Synchronisierung und die Bereitstellung von Fachwissen, Technologien und Fähigkeiten. Weitere Informationen zur DTRA erhalten Sie unter http://www.dtra.mil. MeMed engagiert sich für die Verbesserung der Lebensqualität von Patienten durch Forschung, Entwicklung und Vermarktung von bahnbrechenden Testverfahren, die den Immunstatus des Körpers überwachen. Die Tests von MeMed entschlüsseln die individuellen Reaktionen des Immunsystems auf unterschiedliche Gesundheits- und Erkrankungsstadien. Das Unternehmen konzentriert sich auf die Bereitstellung schneller, genauer und verfolgbarer Diagnostiklösungen für akute Infektionserkrankungen sowie Entzündungskrankheiten in Krankenhäusern und Gemeinden. ImmunoXpert™, das Testverfahren der ersten Generation des Unternehmens, hat die Fähigkeit bewiesen, genau zu erkennen, ob ein Patient an einer bakteriellen oder einer Viruserkrankung leidet. Dadurch werden Ärzte in die Lage versetzt, fundiertere Entscheidungen darüber zu treffen, ob eine Behandlung mit Antibiotika angezeigt ist. ImmunoXpert wurde für die klinische Verwendung in der Europäischen Union, der Schweiz und in Israel freigegeben. Zurzeit wird es in diesen Gebieten zu Proben verwendet. Eine weitere kommerzielle Verbreitung ist im Gang. Das Testverfahren der zweiten Generation von MeMed für schnelle Tests vor Ort (innerhalb von Minuten) befindet sich in der Entwicklung. Weitere Informationen erhalten Sie unter http://www.me-med.com.


"Wir freuen uns über diesen Vertrauensbeweis. Die Anerkennung unserer Arbeit durch die DTRA stärkt die Positionierung von MeMed als Weltmarktführer auf dem Gebiet der immunbasierten Diagnostik von Infektionskrankheiten", bemerkte Dr. Eran Eden, CEO bei MeMed.  "Diese gemeinsame Anstrengung und unsere wachsende Zusammenarbeit mit anderen internationalen Interessenvertretern aus Industrie und Regierung wird die weltweite Verfügbarkeit unserer Tests zur Bekämpfung antimikrobieller Resistenzen ermöglichen." Während der letzten acht Jahre haben die Unternehmensmitgründer Dr. med. Kfir Oved und Dr. Eran Eden mit führenden Forschern und Klinikern aus der ganzen Welt zusammengearbeitet, um die Veränderungen zu untersuchen, die im menschlichen Immunsystem stattfinden, wenn es Infektionen bekämpft, und um eine menschliche Immunsignatur zu entwickeln, die den Unterschied zwischen bakteriellen und Virusinfektionen genau erkennt. ImmunoXpert™, das neuartige Testverfahren der ersten Generation, ist bereits in Gebrauch und hat sich an Tausenden von Patienten bewährt*. Das Testverfahren der zweiten Generation umfasste die Entwicklung einer neuen patientennahen Diagnoseplattform, die einfach zu handhaben ist und nur 15 Minuten Zeit in Anspruch nimmt. "Diese Zusammenarbeit wird uns ermöglichen, die Fertigstellung unserer patientennahen Diagnoseplattform zu beschleunigen", sagte Dr. med. Kfir Oved, CTO bei MeMed. "Die neue Plattform ermöglicht nicht nur innerhalb von Minuten Messungen unserer bakteriellen Tests im Vergleich zu viralen Tests, sondern ebnet darüber hinaus den Weg zu einer Vielzahl von Mehrfach-Proteinmessungen in Form von Schnelltests mit der Präzision einer Labordiagnostik für einen umfassenden Anwendungsbereich." "Das Projekt wird außerdem unser Testmenü zum frühen Erkennen von Infektionen bewerten und erweitern, sogar bereits in einem präsymptomatischen Krankheitsstadium, in dem noch keine Symptome vorliegen. Dies stellt zurzeit eine enorme Einschränkung unserer Fähigkeit dar, Infektionen und Epidemien unter Kontrolle zu halten", stellte Dr. Tanya Gottlieb, VP Scientific Affairs bei MeMed, fest. Die Defense Threat Reduction Agency (DTRA) wurde im Jahr 1998 als eine dem Verteidigungsministerium der Vereinigten Staaten angeschlossene Behörde gegründet und befasst sich mit der Verminderung der Bedrohung durch Massenvernichtungswaffen. Die Hauptaufgabe der DTRA besteht darin, die Bedrohung der Vereinigten Staaten und der restlichen Welt durch globale Massenvernichtungswaffen sowie improvisierte Bedrohungen einzudämmen. Dies geschieht durch Integration, Synchronisierung und die Bereitstellung von Fachwissen, Technologien und Fähigkeiten. Weitere Informationen zur DTRA erhalten Sie unter http://www.dtra.mil. MeMed engagiert sich für die Verbesserung der Lebensqualität von Patienten durch Forschung, Entwicklung und Vermarktung von bahnbrechenden Testverfahren, die den Immunstatus des Körpers überwachen. Die Tests von MeMed entschlüsseln die individuellen Reaktionen des Immunsystems auf unterschiedliche Gesundheits- und Erkrankungsstadien. Das Unternehmen konzentriert sich auf die Bereitstellung schneller, genauer und verfolgbarer Diagnostiklösungen für akute Infektionserkrankungen sowie Entzündungskrankheiten in Krankenhäusern und Gemeinden. ImmunoXpert™, das Testverfahren der ersten Generation des Unternehmens, hat die Fähigkeit bewiesen, genau zu erkennen, ob ein Patient an einer bakteriellen oder einer Viruserkrankung leidet. Dadurch werden Ärzte in die Lage versetzt, fundiertere Entscheidungen darüber zu treffen, ob eine Behandlung mit Antibiotika angezeigt ist. ImmunoXpert wurde für die klinische Verwendung in der Europäischen Union, der Schweiz und in Israel freigegeben. Zurzeit wird es in diesen Gebieten zu Proben verwendet. Eine weitere kommerzielle Verbreitung ist im Gang. Das Testverfahren der zweiten Generation von MeMed für schnelle Tests vor Ort (innerhalb von Minuten) befindet sich in der Entwicklung. Weitere Informationen erhalten Sie unter http://www.me-med.com.


"The data presented at the ESTRO 36 meeting continue to show that the benefits of the TomoTherapy® System's ring gantry platform and daily 3D  image guidance in the treatment of a range of clinical indications." said Fabienne Hirigoyenberry, VP Global Medical and Scientific Affairs of Accuray. "The Radixact™ System, the latest generation TomoTherapy platform, provides the same unrivaled delivery capabilities while giving clinicians the versatility to treat the broad spectrum of patients and disease types with the highest level of precision and increased speed and efficiency." Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures, and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com.http://www.accuray.com. Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's reports on Form 10-Q, filed on November 1, 2016, February 3, 2017, and May 5, 2017, and as updated periodically with the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.


News Article | May 11, 2017
Site: www.businesswire.com

LONDON & WILMINGTON, N.C.--(BUSINESS WIRE)--Chiltern, a leading global contract research organization, will host a complimentary Xtalks webinar, “Imaging Diagnostics and Theranostics: Meeting Clinical Development Challenges.” The live session will feature thought leaders from Chiltern speaking about the new tools that have evolved in the imaging diagnostic and theranostic space and the opportunities they provide to improve the diagnosis and treatment of cancers and other diseases. “Although challenges remain, this is an exciting time to be in clinical research,” said Sapna Hornyak, MS, MBA, executive vice president, medical device & diagnostics. “This presentation will introduce viewers to the diagnostic and theranostic agents currently under development and discuss the ways they are being implemented and utilized.” Among the key topics to be discussed are innovative tools for diagnostic imaging and treatment of cancers and other diseases, the regulatory expectations for these products, and the clinical development challenges they represent. The webinar will take place May 17 at 10 a.m. (EDT). Register at ChilternWebinar.com. To learn more about this topic or get in touch with Chiltern’s Medical Device & Diagnostics team, visit Chiltern.com or schedule a meeting at the SNMMI 2017 Annual Meeting, June 10–14, in Denver, Colorado. About Chiltern Chiltern, a global contract research organization, is a leading provider of clinical services and solutions in a variety of therapeutic areas with engagement models for biopharmaceutical and medical device industries. Chiltern’s team of more than 4,300, located across 47 countries, provides comprehensive Clinical Development, Medical & Scientific Affairs, Data & Analysis, Pharmacovigilance and Strategic Regulatory services using a collaborative approach for more efficient clinical trials. Visit Chiltern.com to learn more about how Chiltern is Designed Around You®.


The CyberKnife System provides benefits for primary cases, recurrent and metastatic diseases The CyberKnife System was designed to deliver treatment beams of different size and shape from hundreds of non-coplanar, isocentric or non-isocentric angles around the patient, enabling the clinician to deliver high-quality treatment plans with extreme precision, sparing surrounding healthy tissue and structures. The system's tracking capabilities eliminate the need for gating techniques and restrictive head frames, providing greater comfort for the patient. "I am proud to see that the unique capabilities of our radiation therapy delivery systems are enabling clinicians to develop innovative approaches for delivering radiation treatments which make a real difference in their patients' lives," said Fabienne Hirigoyenberry, VP Global Medical and Scientific Affairs of Accuray. "Since 1994 when the first patient was treated with the CyberKnife System, it has set the bar for delivering precise radiation treatments while avoiding healthy tissue. The data presented at ESTRO 36 reinforce the system's benefits and show it is increasingly being used to treat a wide range of cancer cases." Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures, and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com. Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's reports on Form 10-Q, filed on November 1, 2016, February 3, 2017, and May 5, 2017, and as updated periodically with the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-data-presented-at-estro-36-reinforce-unmatched-versatility-and-precision-of-the-cyberknife-system-300455804.html


"The data presented at the ESTRO 36 meeting continue to show that the benefits of the TomoTherapy® System's ring gantry platform and daily 3D  image guidance in the treatment of a range of clinical indications." said Fabienne Hirigoyenberry, VP Global Medical and Scientific Affairs of Accuray. "The Radixact™ System, the latest generation TomoTherapy platform, provides the same unrivaled delivery capabilities while giving clinicians the versatility to treat the broad spectrum of patients and disease types with the highest level of precision and increased speed and efficiency." Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures, and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com. Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's reports on Form 10-Q, filed on November 1, 2016, February 3, 2017, and May 5, 2017, and as updated periodically with the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-data-reinforce-benefits-of-tomotherapy-platform-for-mainstream-radiation-therapy-treatment-indications-300455781.html


News Article | May 10, 2017
Site: www.prnewswire.com

The American Academy of Orthopaedic Surgeons estimates about 53,000 people in the United States have shoulder replacement surgery each year. The benefits of replacing both sides of the joint with a total shoulder arthroplasty have been well established, however, glenoid loosening remains the Achilles Heel of the procedure. "According to the literature, 2-10% of patients treated with a standard total shoulder replacement will require a revision procedure within the first decade following surgery due to onlay glenoid component loosening. Inlay arthroplasty may provide a solution to lower the revision burden on patients and the healthcare system," said Matthias Schurhoff, VP of Clinical Operations and Scientific Affairs at Arthrosurface. The company's OVO™ Primary Stemless Shoulder System with inlay glenoid replacement was launched in the US in 2009 and has experienced excellent surgeon adoption. The inherent advantages are particularly well suited for younger and active patients requiring shoulder joint replacement surgery. Arthrosurface, Inc. is a global orthopedic medical technology business providing a broad portfolio of essential products and instrumentation used to treat upper and lower extremity conditions caused by trauma, injury and arthritic disease. The product offerings include devices, instruments and orthobiologics designed to preserve and restore joints so patients can regain and maintain an active lifestyle. The Company offers a variety of unique systems that provide less invasive technologies for surgeons in the treatment of a wide variety of joint pathologies. Founded in 2002, Arthrosurface markets and distributes its products in the US and around the world and has succeeded in helping patients return to activity for over 13 years. For more information, please go to our website at www.arthrosurface.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shoulder-basic-science-reconfirms-benefits-of-inlay-arthroplasty-300455516.html


News Article | May 9, 2017
Site: www.eurekalert.org

ORION is a new collaborative European project to explore ways in which research and funding organizations in life sciences and biomedicine can open up the way they fund, organize and do research. Open science is a core strategy of the European Commission that involves widening participation and collaboration as well as sharing research processes and outcomes to improve research and innovation. All European Union members recognise the benefits of open science, but the transition to "openness" is challenging. The ORION project will help research and funding organizations to understand existing challenges in Open Science and implement institutional, cultural, and behavioral changes in how they carry out and manage research. "New models of working require novel cooperative approaches that engage lots of different actors, such as researchers, funders, publishers, patient organisations, citizens, students, teachers, or companies," explains Michela Bertero, coordinator of the ORION project and responsible for International and Scientific Affairs at the Centre for Genomic Regulation in Barcelona, Spain. "It is often difficult to open up fundamental research in life sciences and biomedicine to different stakeholders, particularly citizens, so the ORION project will be both challenging and interesting," she adds. At the heart of the project will be open "co-creation" experiments that engage multiple stakeholders and explore different ways to make scientific research more participatory and inclusive. The experiments will tackle questions such as: how can research organisations receive input from a multitude of stakeholders? How can research funding be made more inclusive? How can public dialogue inform research policy and research content? How can citizens be involved in fundamental research projects? We will organize, for example, open dialogues with multiple actors on controversial research topics and launch innovative projects on fundamental research that entail participation of citizens and different experts. The results from the experiments will be developed into good practice and concrete actions that research and funding organisations can implement. ORION will also generate new training content for professionals working in funding agencies, to raise knowledge and awareness about Open Science and RRI, Responsible research and innovation. RRI is a concept helping organisations to incorporate the principles of ethics, gender, good governance, open access, public engagement, and science education in their policies, practices and processes. Focus will be on controversial research topics, e.g. animal research, genome editing, personalised medicine or stem cell research, and their medical applications. Partners are committed to sharing lessons learnt and case studies with other organisations as well as developing a tailored action plan on Open Science and RRI for their own organisation. The project will result in a wide range of material, training, good practices, reports and publications that will be disseminated freely and widely across Europe. ORION is a four-year project with a 3.2 million Euros budget funded under the European Commission's Horizon 2020 programme. Partners in the consortium (see list below) represent a mixture of expertise in fundamental research in life sciences and biomedicine, social sciences, funding, science communication, public engagement, and civil society. The project will be working closely with EU-LIFE, an alliance of top life science research institutes in 13 European countries.


GUANGZHOU, China--(BUSINESS WIRE)--Mannatech®, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, has assembled a group of top-tier, independent scientists to lead its Global Scientific Advisory Board that will support the company’s continued commitment to providing groundbreaking, science-backed nutritional supplements to its worldwide customer base. Mannatech provides top-quality nutritional supplements for families in China through its website www.MeiTaiChina.com. Mannatech’s products include the innovative fat-loss system, TruHealth™ and its family of unmatched Ambrotose® nutritional products. “The members of Mannatech’s Global Scientific Advisory Board are committed to science and the truth that their research and findings bring,” said Mannatech’s CEO and President, Alfredo “Al” Bala. “Mannatech has built its worldwide business on science-backed product technology, and this group will help us continue that tradition and take us into new, transformational areas of health and wellness, while ensuring we stay on the path of scientific proof and validation.” This Global Scientific Advisory Board is part of CEO and President Al Bala’s vision for ensuring that Mannatech delivers innovative nutritional technology and products that are supported by clinical trials and scientific validation. The board safeguards that Mannatech products are what they say they are and can provide real results by improving the overall wellness of customers. Mannatech’s Global Scientific Advisory Board is specifically charged to review each new and existing product to ensure ingredients and formulations are kept to a high standard and are in-line with the latest research. The board will also be called upon to make suggestions for new products. Additionally, board members will provide education and training to Associates and customers on health and wellness topics. The Mannatech Global Scientific Advisory Board consists of third-party, independent scientists from around the world. The board members include: Mannatech’s Senior Global Wellness Director, Dr. Steve Nugent, will serve as Chairman of the Global Scientific Advisory Board and Dr. Rolando Maddela, Mannatech’s Director of Clinical Research and Scientific Affairs will serve as the Executive Secretary. Mr. Tait Switzer, Vice President of Research and Development will also support the scientific advisory board members. “Innovative technology supported by a sound scientific foundation is at the heart of Mannatech’s products and ultimately, its success,” said Dr. Nugent. “Mannatech’s Global Scientific Advisory Board will ensure that we remain on the cutting edge of nutritional technology. This is an amazing group of minds that are focused on making the world a better place. By working together, we can find more ways to improve the health and wellness of as many people as possible. These individuals will retain their independence, but their position on the advisory board will give them a unique vantage point to the health and wellness community around the globe, as well as an opportunity to share their point of view with an audience that is in need of their service.” Mannatech’s commitment to science includes clinical studies on its product technology and a global patent program. Since its founding, Mannatech has invested more than $50 million in research and development that includes a clinical testing program for a number of its products that helps supports core product claims and ensures that the company delivers what is promised Mannatech’s core technology has been included in 17 human clinical trials that have been published, 12 of which were double-blind, placebo-controlled studies — the gold standard for product validation. Mannatech’s Global Science Advisory Board began its work in 2016 and meets to provide input to Mannatech on a regular basis. For more information about Mannatech and its products, please visit www.MeiTaiChina.com. †^ Mannatech, Incorporated, offers a profound wellness experience that makes a difference in the lives of people across the world. Through its innovative Glyconutrition products, Mannatech changes lives, providing an unprecedented level of natural wellness, freedom and purpose. With more than 20 years of experience and operations in 26 markets, Mannatech is committed to transforming lives. For more information, visit www.MeiTaiChina.com. †Customers who invite other customers to the Mannatech China cross-border e-commerce site gain rewards for future product purchases or cash redemption. The e-commerce business model is not multi-level marketing or direct selling. ^Mannatech’s cross-border e-commerce model in China is a different opportunity from Mannatech’s MLM business in other markets. Our cross-border e-commerce model in China is not an MLM or direct selling business.


"Innovations in theoretical and computational chemistry underpin our understanding of biological interactions, chemical dynamics and structure, as well as many beneficial chemical technologies. Michele Parrinello is a giant in the field, whose innovations are widely used in chemistry, biology, materials science, and engineering," stated Matthew Tirrell, Chair of the Dreyfus Foundation Scientific Affairs Committee and Founding Pritzker Director of the Institute for Molecular Engineering at the University of Chicago. The impact of Parrinello's work is such that he is one of the most cited scientists in the present day. He is renowned for co-devising the Car–Parrinello method for computer simulation of the movements of atoms and molecules. This work brought together, for the first time, the classical approach of molecular dynamics with a quantum theoretical approach for electron densities. This enabled the realistic exploration of a wide range of physical situations. Prior to this Parrinello had become distinguished for developing the Parrinello–Rahman method to study phase transitions in crystals. More recently, he has developed what is called metadynamics and subsequently announced an efficient variational sampling process. This has allowed the calculation of complicated phenomena such as protein folding, crystallization from a liquid, or the binding of drugs to protein receptors. Henry C. Walter, President of the Dreyfus Foundation, said, "Michele Parrinello's contributions to chemistry are immense. The Dreyfus Foundation is proud to honor him with the Dreyfus Prize, and as the first recipient from outside the United States." "I am overjoyed and humbled by the honor," said Parrinello. "I would like to dedicate this prize to my mentor Anees Rahman, the founder of modern atomistic molecular dynamics, a superb scientist, and a great human being. It was my good fortune to have met him as well as the very many talented colleagues and students with whom I had the pleasure to collaborate." Born in Messina, Italy, Parrinello received his Italian Laurea in physics from the University of Bologna in 1968. He has received many international honors including the Dirac Medal, the Rahman Prize, the Hewlett-Packard Europhysics Prize (all with Roberto Car), the Schroedinger Medal, the Enrico Fermi Prize, and the American Chemical Society Award in Theoretical Chemistry. He is a Fellow of the American Physical Society, Socio corrispondente of the Accademia Nazionale dei Lincei (Italy), and a Member of the Royal Society (UK), the European Academy of Sciences, the National Academy of Sciences, the American Academy of Arts and Sciences, and others. The Camille and Henry Dreyfus Foundation (www.dreyfus.org), based in New York, is a leading non-profit organization devoted to the advancement of the chemical sciences. It was established in 1946 by chemist, inventor, and businessman Camille Dreyfus, who directed that the Foundation's purpose be "to advance the science of chemistry, chemical engineering, and related sciences as a means of improving human relations and circumstances throughout the world." In broad terms, the Foundation programs advance young faculty of early accomplishment, develop leadership in environmental chemistry, and fund lectureships at primarily undergraduate institutions. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/michele-parrinello-wins-the-dreyfus-prize-for-advances-in-theoretical-and-computational-chemistry-300456587.html

Loading Scientific Affairs collaborators
Loading Scientific Affairs collaborators